Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response
Maddalena Marconato, Irène A. Abela, Anthony Hauser, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 12
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

The development of COVID-19 treatment
Yongliang Yuan, Baihai Jiao, Lili Qu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 150
Mpox (formerly monkeypox): pathogenesis, prevention and treatment
Junjie Lu, Hui Xing, Chunhua Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 54
Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy
Arturo Casadevall, Michael J. Joyner, Liise-anne Pirofski, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 5, pp. 381-395
Closed Access | Times Cited: 25
Convalescent plasma and predictors of mortality among hospitalized patients with COVID-19: a systematic review and meta-analysis
Massimo Franchini, Mario Cruciani, Carlo Mengoli, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 12, pp. 1514-1522
Closed Access | Times Cited: 8
Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma
Quigly Dragotakes, Patrick W. Johnson, Matthew R. Buras, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 41
Open Access | Times Cited: 5
Estimates of Actual and Potential Lives Saved in the United States from the use of COVID-19 Convalescent Plasma
Quigly Dragotakes, Patrick W. Johnson, Matthew R. Buras, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Prevalence and clinical relevance of viraemia in viral respiratory tract infections: a systematic review
Karl Hagman, Tamara Postigo, David Diez-Castro, et al.
The Lancet Microbe (2024), pp. 100967-100967
Open Access | Times Cited: 4
One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients
Sixten Körper, Beate Grüner, Daniel Zickler, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 24
Open Access | Times Cited: 21
SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays
Alina Seidel, Simone Hoffmann, Bernd Jahrsdörfer, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study
Sammy Huygens, Tim Preijers, Francis Swaneveld, et al.
Clinical Pharmacokinetics (2024) Vol. 63, Iss. 4, pp. 497-509
Open Access | Times Cited: 3
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection
Irène A. Abela, Magdalena Schwarzmüller, Agnė Ulytė, et al.
mBio (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 2
Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection
Lindsay Wieczorek, Michelle Zemil, Mélanie Merbah, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study
Luther A. Bartelt, Alena J. Markmann, Bridget Nelson, et al.
mBio (2022) Vol. 13, Iss. 5
Open Access | Times Cited: 12
Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review
Usha Rani Kandula, Techane Sisay Tuji, Dinkinesh Begna Gudeta, et al.
Journal of Blood Medicine (2023) Vol. Volume 14, pp. 159-187
Open Access | Times Cited: 7
Booster Immunization Improves Memory B Cell Responses in Older Adults Unresponsive to Primary SARS-CoV-2 Immunization
Marije K. Verheul, Kim H. Nijhof, Mary‐lène de Zeeuw‐Brouwer, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1196-1196
Open Access | Times Cited: 7
Immune Plasma for the Treatment of COVID-19: Lessons Learned so far
Hubert Schrezenmeier, Simone Hoffmann, Henrike Hofmann, et al.
Hämostaseologie (2023) Vol. 43, Iss. 01, pp. 067-074
Open Access | Times Cited: 5
COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial
Feben Habtehyimer, Xianming Zhu, Andrew D. Redd, et al.
Microbiology Spectrum (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 5
The Natural History of SARS-CoV-2-Incurred Disease: From Infection to Long COVID
Kung–Hao Liang, Yuan‐Chi Teng, Yiting Liao, et al.
International Journal of Translational Medicine (2024) Vol. 4, Iss. 1, pp. 72-86
Open Access | Times Cited: 1
Altered Liver Enzyme Markers in Patients with Asymptomatic, and Mild Omicron Infection: A Retrospective Study
Xi Cao, Yongli Xie, Jian-Ying Yi, et al.
Journal of Inflammation Research (2024) Vol. Volume 17, pp. 6875-6885
Open Access | Times Cited: 1
Efficacy of convalescent plasma in hospitalized COVID-19 patients: findings from a controlled trial
Tânia Portella Costa, Mateus Nóbrega Aoki, Camilla Moreira Ribeiro, et al.
Brazilian Journal of Medical and Biological Research (2024) Vol. 57
Open Access | Times Cited: 1
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial
Maxime Desmarets, Simone Hoffmann, Charline Vauchy, et al.
BMJ Open (2023) Vol. 13, Iss. 4, pp. e071277-e071277
Open Access | Times Cited: 4
Introduction of an Ultraviolet C-Irradiated 4T1 Murine Breast Cancer Whole-Cell Vaccine Model
Gábor J. Szebeni, Róbert Alföldi, L Nagy, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1254-1254
Open Access | Times Cited: 3
Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort Study
Irène A. Abela, Anthony Hauser, Magdalena Schwarzmüller, et al.
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 2, pp. e292-e304
Open Access
Evaluating tixagevimab/cilgavimab prophylaxis in allogeneic haematopoietic cell transplantation recipients for COVID‐19 prevention
Julia Trepl, Chloé Pasin, Dominik Schneidawind, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 5, pp. 1908-1912
Open Access
The clinical characteristics analysis of serum markers for the cardiovascular system in early-stage COVID-19 patients
Xi Cao, Yongli Xie, Jian-ying Yi, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access
Page 1 - Next Page

Scroll to top